Corrigendum to “Identification of Differential Tumor Subtypes of T1 Bladder Cancer” [Eur. Urol. 78 (2020) 533–537] (European Urology (2020) 78(4) (533–537), (S030228382030508X), (10.1016/j.eururo.2020.06.048))

A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, Xiaoqi Lin, Kimberly A. McLaughlin, Arighno Das, Leigh Ann Fall, Damiano Fantini, Timothy J. Taxter, Lauren S. Mogil, Sia Viborg Lindskrog, Lars Dyrskjøt, David J. McConkey, Robert S. Svatek, Aurélien de Reyniès, Mauro A.A. Castro, Joshua J. Meeks*

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original article, the name of author Xiaoqi Lin was incorrectly given as Xiquo Lin. Conflicts of interest: Joshua J. Meeks is a consultant for Ferring, AstraZeneca, and Janssen and has participated in advisory boards for Foundation Medicine and Nucleix. The remaining authors have nothing to disclose.

Original languageEnglish (US)
Pages (from-to)e53
JournalEuropean urology
Volume81
Issue number2
DOIs
StatePublished - Feb 2022

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Corrigendum to “Identification of Differential Tumor Subtypes of T1 Bladder Cancer” [Eur. Urol. 78 (2020) 533–537] (European Urology (2020) 78(4) (533–537), (S030228382030508X), (10.1016/j.eururo.2020.06.048))'. Together they form a unique fingerprint.

Cite this